Abstract:Alzheimer's disease (AD) is a neurodegenerative disorder marked by significant loss of central cholinergic neurons. This progressive deterioration leads to cognitive dysfunction and impaired motor activity, culminating in the brain cell's death at the later stages of the disease. The approved drugs for AD are limited to providing symptomatic relief for an initial period due to the multifaceted etiology of the disease. Several studies have demonstrated that rivastigmine (RIV) is a selectively potent inhibitor of butyrylcholinesterase and devoid of antioxidant, Aβ, and tau protein aggregation inhibition and anti-inflammatory properties. Therefore, to address these issues associated with RIV, novel rivastigmine-based molecules were rationally designed, synthesized, and evaluated in various in-vitro and in-vivo AD models. In in-vitro acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibition studies revealed that 3q & 6e as promising leads (AChE, IC 50 1.72 ± 0.15, 0.91 ± 0.016 μ M, BChE, IC 50 6.69 ± 0.28 μM, 1.19 ± 0.026 μ M, for 3q & 6e , respectively) . The computational studies (molecular docking and dynamics) further corroborated the in-vitro studies. Further, 3q and 6e were found to be potent antioxidants in the DPPH assay (IC 50 16.15 ± 1.05 & 15.17 ± 0.07 μM, for 3q & 6e , respectively). Interestingly, 3q, and 6e could effectively inhibit self-induced full-length tau and Aβ 1-42 aggregation. Treatment with 3q & 6e inhibited microglial activation by attenuating ROS release and mitochondrial damage. Further, 3q & 6e also suppressed NLRP3 inflammasome and NF-κB expression levels in microglial cells and halted the release of pro-inflammatory cytokines in human microglial cells Finally, 3q & 6e were found to be efficacious in reversing the scopolamine-induced memory impairment in the Morris water maze test. The expression of various neuroprotection markers, such as BDNF and TRKB, was significantly overexpressed compared to the disease control group.

Discovery of Novel Rivastigmine-Hydroxycinnamic Acid Hybrids As Multi-Targeted Agents for Alzheimer's Disease.

Design, Synthesis and Biological Evaluation of 2-Styryl-5-hydroxy-4-pyrone Derivatives and Analogues As Multiple Functional Agents with the Potential for the Treatment of Alzheimer's Disease.

Novel 1-phenyl-3-hydroxy-4-pyridinone derivatives as Multifunctional Agents for the therapy of Alzheimer's Disease.

Design, Synthesis and Evaluation of Rivastigmine and Curcumin Hybrids As Site-Activated Multitarget-Directed Ligands for Alzheimer's Disease Therapy.

Novel Donepezil-Chalcone-rivastigmine Hybrids As Potential Multifunctional Anti-Alzheimer's Agents: Design, Synthesis, in Vitro Biological Evaluation, in Vivo and in Silico Studies.

New Multitarget Rivastigmine–Indole Hybrids as Potential Drug Candidates for Alzheimer's Disease

New Multi-Target-directed Small Molecules Against Alzheimer's Disease: a Combination of Resveratrol and Clioquinol.

Design, Synthesis, and Biological Evaluation of Novel Chromanone Derivatives as Multifunctional Agents for the Treatment of Alzheimer's Disease

Design, Synthesis and Biological Evaluation of New Coumarin-Dithiocarbamate Hybrids As Multifunctional Agents for the Treatment of Alzheimer's Disease

Searching for the Multi-Target-Directed Ligands Against Alzheimer’s Disease: Discovery of Quinoxaline-Based Hybrid Compounds with AChE, H3R and BACE 1 Inhibitory Activities

Nature-based Molecules Combined with Rivastigmine: A Symbiotic Approach for the Synthesis of New Agents Against Alzheimer's Disease.

Rivastigmine–Benzimidazole Hybrids as Promising Multitarget Metal-Modulating Compounds for Potential Treatment of Neurodegenerative Diseases

Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity

Design, Synthesis, and Biological Evaluation of Novel Tetrahydroacridin Hybrids with Sulfur-Inserted Linkers as Potential Multitarget Agents for Alzheimer's Disease

Rational Design of Novel Selective Dual-Target Inhibitors of Acetylcholinesterase and Monoamine Oxidase B as Potential anti-Alzheimer's Disease Agents.

Discovery of novel melatonin–mydroxyquinoline hybrids as multitarget strategies for Alzheimer's disease therapy

Discovery of novel substituted (Z)-N'-hydroxy-3-(3-phenylureido)benzimidamide derivatives as multifunctional molecules targeting pathological hallmarks of Alzheimer's disease

Design, Synthesis and Biological Evaluation of Novel Carboline-Cinnamic Acid Hybrids As Multifunctional Agents for Treatment of Alzheimer's Disease.

Novel coumarin derivatives as multifunctional anti-AD agents: Design, synthesis, X-ray crystal structure and biological evaluation

Design, synthesis and pharmacological evaluation of novel tacrine-caffeic acid hybrids as multi-targeted compounds against Alzheimer's disease.

Design, Synthesis and Evaluation of Novel Dual Monoamine-Cholinesterase Inhibitors As Potential Treatment for Alzheimer’s Disease